nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0318	0.0625	CcSEcCtD
Dextroamphetamine—SLC18A2—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.0242	0.103	CbGpPWpGaD
Dextroamphetamine—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.0233	0.0458	CcSEcCtD
Dextroamphetamine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.0211	0.0824	CbGeAlD
Dextroamphetamine—TAAR1—nervous system—amyotrophic lateral sclerosis	0.0185	0.0721	CbGeAlD
Dextroamphetamine—TAAR1—central nervous system—amyotrophic lateral sclerosis	0.0178	0.0694	CbGeAlD
Dextroamphetamine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.0177	0.0348	CcSEcCtD
Dextroamphetamine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.0171	0.0665	CbGeAlD
Dextroamphetamine—Injury—Riluzole—amyotrophic lateral sclerosis	0.0163	0.032	CcSEcCtD
Dextroamphetamine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.0161	0.0317	CcSEcCtD
Dextroamphetamine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.0158	0.0617	CbGeAlD
Dextroamphetamine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.0148	0.0292	CcSEcCtD
Dextroamphetamine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.0147	0.029	CcSEcCtD
Dextroamphetamine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.0146	0.0287	CcSEcCtD
Dextroamphetamine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.0142	0.0279	CcSEcCtD
Dextroamphetamine—SLC18A2—brainstem—amyotrophic lateral sclerosis	0.012	0.0468	CbGeAlD
Dextroamphetamine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.0119	0.0234	CcSEcCtD
Dextroamphetamine—ADRA1A—hindbrain—amyotrophic lateral sclerosis	0.0119	0.0463	CbGeAlD
Dextroamphetamine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0232	CcSEcCtD
Dextroamphetamine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.0117	0.023	CcSEcCtD
Dextroamphetamine—Depression—Riluzole—amyotrophic lateral sclerosis	0.0115	0.0226	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0223	CcSEcCtD
Dextroamphetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.0113	0.0482	CbGpPWpGaD
Dextroamphetamine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0222	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.0112	0.022	CcSEcCtD
Dextroamphetamine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0217	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00979	0.0192	CcSEcCtD
Dextroamphetamine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00908	0.0354	CbGeAlD
Dextroamphetamine—SLC6A3—Parkinsons Disease Pathway—ATXN2—amyotrophic lateral sclerosis	0.00891	0.0379	CbGpPWpGaD
Dextroamphetamine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00884	0.0174	CcSEcCtD
Dextroamphetamine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00875	0.0172	CcSEcCtD
Dextroamphetamine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00844	0.0166	CcSEcCtD
Dextroamphetamine—SLC18A2—medulla oblongata—amyotrophic lateral sclerosis	0.00837	0.0326	CbGeAlD
Dextroamphetamine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00828	0.0163	CcSEcCtD
Dextroamphetamine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00823	0.0162	CcSEcCtD
Dextroamphetamine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00796	0.0157	CcSEcCtD
Dextroamphetamine—SLC18A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00786	0.0335	CbGpPWpGaD
Dextroamphetamine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00781	0.0153	CcSEcCtD
Dextroamphetamine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00778	0.0153	CcSEcCtD
Dextroamphetamine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00767	0.0151	CcSEcCtD
Dextroamphetamine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00764	0.015	CcSEcCtD
Dextroamphetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00762	0.0325	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0075	0.0148	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00735	0.0145	CcSEcCtD
Dextroamphetamine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00732	0.0285	CbGeAlD
Dextroamphetamine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00731	0.0144	CcSEcCtD
Dextroamphetamine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00718	0.0141	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00711	0.014	CcSEcCtD
Dextroamphetamine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00701	0.0138	CcSEcCtD
Dextroamphetamine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.007	0.0273	CbGeAlD
Dextroamphetamine—ADRA1A—brainstem—amyotrophic lateral sclerosis	0.00681	0.0265	CbGeAlD
Dextroamphetamine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00675	0.0288	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neurotransmitter Release Cycle—CHAT—amyotrophic lateral sclerosis	0.00674	0.0287	CbGpPWpGaD
Dextroamphetamine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00665	0.0131	CcSEcCtD
Dextroamphetamine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00656	0.0129	CcSEcCtD
Dextroamphetamine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00654	0.0129	CcSEcCtD
Dextroamphetamine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00647	0.0127	CcSEcCtD
Dextroamphetamine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00639	0.0126	CcSEcCtD
Dextroamphetamine—ADRA1B—nervous system—amyotrophic lateral sclerosis	0.00635	0.0247	CbGeAlD
Dextroamphetamine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00635	0.0125	CcSEcCtD
Dextroamphetamine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00634	0.0125	CcSEcCtD
Dextroamphetamine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00629	0.0124	CcSEcCtD
Dextroamphetamine—SLC18A2—nervous system—amyotrophic lateral sclerosis	0.00629	0.0245	CbGeAlD
Dextroamphetamine—ADRA1B—central nervous system—amyotrophic lateral sclerosis	0.00611	0.0238	CbGeAlD
Dextroamphetamine—SLC18A2—central nervous system—amyotrophic lateral sclerosis	0.00605	0.0236	CbGeAlD
Dextroamphetamine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00601	0.0118	CcSEcCtD
Dextroamphetamine—SLC18A2—Neurotransmitter Release Cycle—SLC6A1—amyotrophic lateral sclerosis	0.006	0.0256	CbGpPWpGaD
Dextroamphetamine—SLC18A2—cerebellum—amyotrophic lateral sclerosis	0.00592	0.0231	CbGeAlD
Dextroamphetamine—ADRA1A—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.00585	0.0249	CbGpPWpGaD
Dextroamphetamine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00584	0.0115	CcSEcCtD
Dextroamphetamine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00581	0.0114	CcSEcCtD
Dextroamphetamine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00581	0.0114	CcSEcCtD
Dextroamphetamine—SLC18A2—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00577	0.0246	CbGpPWpGaD
Dextroamphetamine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00564	0.022	CbGeAlD
Dextroamphetamine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00542	0.0107	CcSEcCtD
Dextroamphetamine—SLC6A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00529	0.0225	CbGpPWpGaD
Dextroamphetamine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00528	0.0104	CcSEcCtD
Dextroamphetamine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00511	0.0199	CbGeAlD
Dextroamphetamine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00503	0.00989	CcSEcCtD
Dextroamphetamine—SLC6A2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00502	0.0214	CbGpPWpGaD
Dextroamphetamine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00486	0.00956	CcSEcCtD
Dextroamphetamine—ADRA1B—brain—amyotrophic lateral sclerosis	0.00485	0.0189	CbGeAlD
Dextroamphetamine—SLC18A2—brain—amyotrophic lateral sclerosis	0.00481	0.0187	CbGeAlD
Dextroamphetamine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00476	0.0185	CbGeAlD
Dextroamphetamine—SLC6A3—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00468	0.02	CbGpPWpGaD
Dextroamphetamine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00468	0.00919	CcSEcCtD
Dextroamphetamine—Rash—Riluzole—amyotrophic lateral sclerosis	0.00464	0.00912	CcSEcCtD
Dextroamphetamine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00463	0.00911	CcSEcCtD
Dextroamphetamine—Headache—Riluzole—amyotrophic lateral sclerosis	0.00461	0.00906	CcSEcCtD
Dextroamphetamine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00458	0.0178	CbGeAlD
Dextroamphetamine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00448	0.0174	CbGeAlD
Dextroamphetamine—SLC6A3—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00445	0.019	CbGpPWpGaD
Dextroamphetamine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00437	0.00859	CcSEcCtD
Dextroamphetamine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00401	0.0156	CbGeAlD
Dextroamphetamine—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.00393	0.0167	CbGpPWpGaD
Dextroamphetamine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00384	0.015	CbGeAlD
Dextroamphetamine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00369	0.0144	CbGeAlD
Dextroamphetamine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00364	0.0142	CbGeAlD
Dextroamphetamine—ADRA1A—nervous system—amyotrophic lateral sclerosis	0.00357	0.0139	CbGeAlD
Dextroamphetamine—ADRA1A—central nervous system—amyotrophic lateral sclerosis	0.00343	0.0134	CbGeAlD
Dextroamphetamine—ADRA1A—cerebellum—amyotrophic lateral sclerosis	0.00336	0.0131	CbGeAlD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00307	0.0131	CbGpPWpGaD
Dextroamphetamine—SLC6A2—brain—amyotrophic lateral sclerosis	0.00293	0.0114	CbGeAlD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00277	0.0118	CbGpPWpGaD
Dextroamphetamine—ADRA1A—brain—amyotrophic lateral sclerosis	0.00273	0.0106	CbGeAlD
Dextroamphetamine—SLC6A3—Parkinsons Disease Pathway—CASP9—amyotrophic lateral sclerosis	0.00267	0.0114	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00255	0.0109	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00235	0.01	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00227	0.00968	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—MAPT—amyotrophic lateral sclerosis	0.00217	0.00925	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00211	0.00899	CbGpPWpGaD
Dextroamphetamine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.0021	0.00819	CbGeAlD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00208	0.00886	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00207	0.00881	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00204	0.00868	CbGpPWpGaD
Dextroamphetamine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.00202	0.00788	CbGeAlD
Dextroamphetamine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00198	0.0077	CbGeAlD
Dextroamphetamine—SLC18A2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00195	0.00832	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00193	0.00823	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00193	0.00823	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00184	0.00785	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00183	0.0078	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.0018	0.00769	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.0018	0.00768	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00174	0.00742	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00172	0.00734	CbGpPWpGaD
Dextroamphetamine—CYP2D6—brain—amyotrophic lateral sclerosis	0.00161	0.00626	CbGeAlD
Dextroamphetamine—SLC18A2—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00159	0.00679	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00157	0.00667	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00152	0.00648	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00149	0.00635	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00148	0.00631	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00148	0.00631	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00145	0.00619	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.0014	0.00598	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.0014	0.00595	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00136	0.00577	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00132	0.00563	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00132	0.00562	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00124	0.00528	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00124	0.00528	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.00121	0.00515	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.00119	0.00508	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00116	0.00496	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00115	0.00491	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00115	0.00491	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00115	0.0049	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.00112	0.00479	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.0011	0.00468	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.00108	0.00462	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00108	0.00458	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00105	0.00449	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00104	0.00442	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.00103	0.00438	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00103	0.00437	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00102	0.00434	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000978	0.00417	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00095	0.00404	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00094	0.004	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000936	0.00399	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000934	0.00398	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000922	0.00393	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000899	0.00383	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000883	0.00376	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000883	0.00376	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000866	0.00369	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000845	0.0036	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000833	0.00355	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000797	0.00339	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000796	0.00339	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000796	0.00339	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000794	0.00338	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000787	0.00335	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000753	0.00321	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000731	0.00312	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000729	0.00311	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00071	0.00302	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000701	0.00299	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000647	0.00276	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—CASP3—amyotrophic lateral sclerosis	0.000645	0.00275	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.00064	0.00273	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00063	0.00268	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000623	0.00265	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—MMP9—amyotrophic lateral sclerosis	0.00061	0.0026	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000558	0.00238	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000536	0.00228	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000536	0.00228	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000535	0.00228	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000534	0.00227	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000521	0.00222	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000478	0.00203	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000475	0.00202	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000475	0.00202	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000474	0.00202	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000473	0.00201	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.00044	0.00187	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000423	0.0018	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000412	0.00176	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000393	0.00167	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—amyotrophic lateral sclerosis	0.00039	0.00166	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—amyotrophic lateral sclerosis	0.000346	0.00147	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000336	0.00143	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000327	0.00139	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000323	0.00137	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000316	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000306	0.0013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000302	0.00129	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000279	0.00119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000274	0.00117	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000272	0.00116	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000268	0.00114	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.00026	0.00111	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000251	0.00107	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000251	0.00107	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000243	0.00104	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000233	0.000993	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000229	0.000977	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000215	0.000915	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000214	0.00091	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000213	0.000908	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000207	0.000882	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000201	0.000856	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.0002	0.000854	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.00019	0.000811	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00019	0.000808	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000184	0.000786	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	0.000181	0.000772	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000178	0.00076	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000169	0.00072	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	0.000165	0.000705	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000164	0.000698	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000164	0.000697	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000162	0.00069	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	0.000156	0.000666	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000145	0.00062	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000144	0.000613	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	0.00014	0.000598	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000137	0.000585	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000135	0.000577	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000132	0.000561	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	0.000127	0.00054	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.00012	0.000512	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.00012	0.00051	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000117	0.000498	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000111	0.000474	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000106	0.000453	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	0.000106	0.000452	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000104	0.000444	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000104	0.000444	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.94e-05	0.000423	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.88e-05	0.000421	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.27e-05	0.000395	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.83e-05	0.000376	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.51e-05	0.000362	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8e-05	0.000341	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.55e-05	0.000322	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.1e-05	0.000303	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.07e-05	0.000301	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.58e-05	0.00028	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.28e-05	0.000267	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.84e-05	0.000249	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.6e-05	0.000238	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.44e-05	0.000232	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.14e-05	0.000219	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.83e-05	0.000206	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	4.23e-05	0.00018	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.18e-05	0.000178	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.95e-05	0.000168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.72e-05	0.000158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.55e-05	0.000151	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.51e-05	0.00015	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.15e-05	0.000134	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.9e-05	0.000124	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.68e-05	0.000114	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.38e-05	0.000102	CbGpPWpGaD
